Adial Pharmaceuticals(ADIL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADIL Adial Pharmaceuticals

Market Closed 07-31 16:00:00 EDT

3.34

+0.05

+1.52%

盘后3.20

-0.14-4.19%

19:34 EDT

High3.39	Low3.20	Vol51.60K
Open3.30	D1 Closing3.29	Amplitude5.78%
Mkt Cap7.31M	Tradable Cap4.62M	Total Shares2.19M
T/O171.62K	T/O Rate3.73%	Tradable Shares1.38M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ADIL","market":"US","secType":"STK","nameCN":"Adial Pharmaceuticals","latestPrice":3.34,"timestamp":1785528000000,"preClose":3.29,"halted":0,"volume":51603,"hourTrading":{"tag":"盘后","latestPrice":3.2,"preClose":3.34,"latestTime":"19:34 EDT","volume":206,"amount":662.33,"timestamp":1785540845983,"change":-0.14,"changeRate":-0.041916,"amplitude":0.041916},"delay":0,"changeRate":0.015197568389057697,"floatShares":1383600,"shares":2188500,"eps":-9.9326,"marketStatus":"Market Closed","change":0.05,"latestTime":"07-31 16:00:00 EDT","open":3.3,"high":3.39,"low":3.2,"amount":171621.515415,"amplitude":0.057751,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.9326,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1785744000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1532664000000,"exchange":"NASDAQ","adjPreClose":3.29,"preHourTrading":{"tag":"盘前","latestPrice":3.2,"preClose":3.29,"latestTime":"09:28 EDT","volume":107,"amount":330.1600025,"timestamp":1785504488008,"change":-0.09,"changeRate":-0.027356,"amplitude":0.036474},"postHourTrading":{"tag":"盘后","latestPrice":3.2,"preClose":3.34,"latestTime":"19:34 EDT","volume":206,"amount":662.33,"timestamp":1785540845983,"change":-0.14,"changeRate":-0.041916,"amplitude":0.041916},"volumeRatio":0.7726480512802105,"impliedVol":1.6275,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/ADIL","defaultTab":"news","newsList":[{"id":"2652842765","title":"Coastlands Capital LP Reports $8,689 Adial Pharmaceuticals Common Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2652842765","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652842765?lang=en_us&edition=fundamental","pubTime":"2026-07-17 05:09","pubTimestamp":1784236154,"startTime":"0","endTime":"0","summary":"Coastlands Capital LP reports $8,689 Adial Pharmaceuticals common share purchaseCoastlands Capital, a 10% owner of Adial Pharmaceuticals, increased its stake through open-market purchases.Holdings ros","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL2nYrlm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Coastlands Capital LP Reports $8,689 Adial Pharmaceuticals Common Share Purchase","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651002117","title":"Coastlands Capital LP Reports Adial Pharmaceuticals Common Share Purchase Worth $32,613.87","url":"https://stock-news.laohu8.com/highlight/detail?id=2651002117","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651002117?lang=en_us&edition=fundamental","pubTime":"2026-07-13 22:31","pubTimestamp":1783953067,"startTime":"0","endTime":"0","summary":"Coastlands Capital LP reports Adial Pharmaceuticals common share purchase worth $32,613.87Coastlands Capital, a 10% owner of Adial Pharmaceuticals, increased its stake to 385,075 common shares.The pur","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260713:nNDL5Gj2Ky:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Coastlands Capital LP Reports Adial Pharmaceuticals Common Share Purchase Worth $32,613.87","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648573675","title":"Major Investor Quietly Boosts Stake in Adial Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2648573675","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648573675?lang=en_us&edition=fundamental","pubTime":"2026-07-02 10:04","pubTimestamp":1782957862,"startTime":"0","endTime":"0","summary":"New insider activity at Adial Pharmaceuticals ( ($ADIL) ) has taken place on July 1, 2026. Significant shareholder Coastlands Capital LP has increa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-boosts-stake-in-adial-pharmaceuticals-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-boosts-stake-in-adial-pharmaceuticals-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648541801","title":"Coastlands Capital LP Buys 25,000 Adial Pharma Shares Worth $65,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2648541801","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648541801?lang=en_us&edition=fundamental","pubTime":"2026-07-01 22:31","pubTimestamp":1782916261,"startTime":"0","endTime":"0","summary":"Coastlands Capital LP buys 25,000 Adial Pharma shares worth $65,000Coastlands Capital LP boosted its stake in Adial Pharmaceuticals, buying 25,000 common shares at $2.6 each.Holdings rose to 373,322 shares, held indirectly through Coastlands Capital LP.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 01, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL1cgvP3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Coastlands Capital LP Buys 25,000 Adial Pharma Shares Worth $65,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647030505","title":"Adial Pharmaceuticals Initial Beneficial Ownership Filing Lists Coastlands Capital LP as 10% Owner","url":"https://stock-news.laohu8.com/highlight/detail?id=2647030505","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647030505?lang=en_us&edition=fundamental","pubTime":"2026-06-30 00:48","pubTimestamp":1782751683,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals initial beneficial ownership filing lists Coastlands Capital LP as 10% ownerAdial Pharmaceuticals Form 3 shows Coastlands Capital LP reporting 10% owner status, triggered by an e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nNDL5vcqZ1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645819755","title":"Coastlands Capital Lp Reports 9.98% Passive Stake in Adial Pharmaceuticals as of June 17 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2645819755","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645819755?lang=en_us&edition=fundamental","pubTime":"2026-06-24 22:36","pubTimestamp":1782311765,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nFWN42W0SB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643573027","title":"Adial Pharmaceuticals Closes First $32 Million Tranche of Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2643573027","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643573027?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:44","pubTimestamp":1781613891,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals  said Tuesday it has closed the first $32 million tranche of its previously announced private placement of up to $64 million, including the conversion of outstanding notes assumed through its acquisition of Azora Therapeutics.The company said the financing was led by Coastlands Capital, with participation from Kern Capital, Boxer Capital Management, Stonepine Capital Management, AuGC BioFund, as well as other institutional investors, insiders and members of management.Adial said proceeds from the financing will support the development of its lead colon-targeted AhR program through upcoming clinical milestones and help drive long-term shareholder value.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643547297","title":"Adial Pharmaceuticals grants inducement equity awards to new chief development officer, strategy EVP","url":"https://stock-news.laohu8.com/highlight/detail?id=2643547297","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643547297?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:04","pubTimestamp":1781611461,"startTime":"0","endTime":"0","summary":"Adial granted inducement equity awards to newly hired Chief Development Officer Matthew Davidson and EVP of Strategy Julie Saiki.Davidson received 424,446 restricted stock units, options for 424,447 shares; Saiki received 132,802 restricted stock units, options for 132,802 shares.Options carry a USD 2.98 exercise price, set off the June 12 close; 10-year term.Portion vests monthly over three years; remaining portion tied to issuance of pre-funded warrants and common warrants under June 11 agreements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL14vRTb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643541227","title":"Adial Pharmaceuticals Expands Executive Leadership Team and Closes Pipe Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2643541227","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643541227?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:00","pubTimestamp":1781611206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nTUA9X0QTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643754226","title":"Press Release: Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2643754226","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643754226?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:00","pubTimestamp":1781611200,"startTime":"0","endTime":"0","summary":"GLEN ALLEN, Va., June 16, 2026  -- Adial Pharmaceuticals, Inc.   today announced that the Company's Compensation Committee and Board of Directors granted Matthew Davidson and Julie Saiki, the Company's newly appointed chief development officer and executive vice president of strategy, respectively, restricted stock units and stock options to purchase Company common stock as an inducement to them becoming employees of the Company in connection with the closing of its business combination with Azora Therapeutics, Inc. , which was previously announced by the Company on June 11, 2026. Additionally, the Company today announced the closing of the first $32 million  of its previously announced up to $64 million private placement.The above grants were approved by the Company's Compensation Committee and Board of Directors and were made as an inducement material to the employees entering into employment with Adial. The grants were made outside of the Compan","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PIPE","TISI","BK4120","BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643755640","title":"Adial Pharmaceuticals director Wendy B. Young files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2643755640","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643755640?lang=en_us&edition=fundamental","pubTime":"2026-06-16 18:11","pubTimestamp":1781604694,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals director Wendy B. Young filed an initial Form 3 on June 16 covering holdings as of June 11.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL12Rbw8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643200358","title":"Adial Pharmaceuticals Initiated at Buy by LUCID CAPITAL MARKETS","url":"https://stock-news.laohu8.com/highlight/detail?id=2643200358","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643200358?lang=en_us&edition=fundamental","pubTime":"2026-06-16 01:26","pubTimestamp":1781544360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ADIL/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 15, 2026 13:26 ET (17:26 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643272241","title":"Adial Pharmaceuticals initiated with a Buy at Lucid Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2643272241","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643272241?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:11","pubTimestamp":1781518309,"startTime":"0","endTime":"0","summary":"Lucid Capital initiated coverage of Adial Pharmaceuticals (ADIL) with a Buy rating and $6 price target The firm says the company’s newly acquired l...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-initiated-with-a-buy-at-lucid-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-initiated-with-a-buy-at-lucid-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LCDL","ADIL","BK4596","BK4551","BK4007","BK4555","BK4099","LCID","LCIZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642391842","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2642391842","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642391842?lang=en_us&edition=fundamental","pubTime":"2026-06-12 03:04","pubTimestamp":1781204653,"startTime":"0","endTime":"0","summary":"Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index adding 1.3% and the State Street Health Care Select Sector SPDR ETF  increasing 1.3%.The iShares Biotechnology ETF  climbed 2.9%.In corporate news, Adial Pharmaceuticals  shares surged 41% after it said Thursday it has acquired Azora Therapeutics, a biopharmaceutical company developing treatments for serious inflammatory diseases.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4585","FDN","BK4588","LU0128526141.USD","LABU","STT","XBI","ADIL","BK4137","BK4581","HCSG","LU0029874061.USD","XLV","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642366802","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2642366802","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642366802?lang=en_us&edition=fundamental","pubTime":"2026-06-12 01:37","pubTimestamp":1781199431,"startTime":"0","endTime":"0","summary":"Propanc Biopharma  approved a share repurchase program to buy back up to $5 million of common stock, the company said Thursday.Shares soared 124% as intraday trading volume catapulted to over 155.6 million from a daily average of about 130,000.Adial Pharmaceuticals  said Thursday it has acquired Azora Therapeutics, a biopharmaceutical company developing treatments for serious inflammatory diseases.Shares soared 30% amid a surge in intraday trading volume to over 16.5 million from a daily average of roughly 118,000.Applied Materials  expanded manufacturing and research & development operations in Singapore with a $500 million facility in Tampines to support AI-driven semiconductor demand.Shares jumped 8.5% following an increase in intraday trading volume to over 5.3 million from a daily average of about 7 million.Price: 3.04, Change: +1.69, Percent Change: +124.81","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0661504455.SGD","LU0354030511.USD","LU1069344957.HKD","LU2089985449.USD","LU2458330243.SGD","LU1815333072.USD","LU1267930813.SGD","LU0868494708.USD","LU1674673691.USD","LU0738911758.USD","IE00BSNM7G36.USD","SG9999002232.USD","LU2458330169.SGD","LU1003077747.HKD","BK4567","LU2089284900.SGD","LU0061475181.USD","ADIL","LU1778281490.HKD","LU1868837136.USD","LU1721428933.USD","AMAT","LU0444971666.USD","BK4585","BK4533","IE00BD6J9T35.USD","LU1917777945.USD","LU2028103732.USD","LU0158827948.USD","BK4518","LU1989763005.USD","LU1989773731.SGD","LU1868836591.USD","LU0957808578.USD","LU1046421795.USD","LU0942090050.USD","LU0096362180.USD","BK4147","BK4588","LU1823568750.SGD","LU0175139822.USD","IE0009356076.USD","IE00BQXX3D17.EUR","LU1674673428.USD","PPCB","LU1868836757.USD","LU2111349929.HKD","LU2413666699.HKD","LU0198837287.USD","LU2413666426.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642923579","title":"Adial Pharmaceuticals Completes Azora Merger, Shifts Strategic Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2642923579","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642923579?lang=en_us&edition=fundamental","pubTime":"2026-06-12 00:57","pubTimestamp":1781197066,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals ( ($ADIL) ) has issued an update. On June 11, 2026, Adial Pharmaceuticals completed the acquisition of Azora Therapeutics, ex...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adial-pharmaceuticals-completes-azora-merger-shifts-strategic-focus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adial-pharmaceuticals-completes-azora-merger-shifts-strategic-focus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642337952","title":"Adial Pharmaceuticals announces acquisition of Azora Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2642337952","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642337952?lang=en_us&edition=fundamental","pubTime":"2026-06-11 23:50","pubTimestamp":1781193009,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals (ADIL) has acquired Azora Therapeutics, a biopharmaceutical company developing treatments for serious inflammatory diseases. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-announces-acquisition-of-azora-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/adial-pharmaceuticals-announces-acquisition-of-azora-therapeutics-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ADIL","BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642423314","title":"Adial Pharmaceuticals adds Wendy Young to board of directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2642423314","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642423314?lang=en_us&edition=fundamental","pubTime":"2026-06-11 23:44","pubTimestamp":1781192699,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals named Wendy Young to its board as it integrates Azora Therapeutics.Young brings 32 years in drug discovery and biopharma leadership, including senior vice president of small-molecule drug discovery at Genentech.Azora co-founder Matt Davidson will join as chief development officer and a newly appointed director.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL7kPknd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642331372","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:44 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2642331372","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642331372?lang=en_us&edition=fundamental","pubTime":"2026-06-11 23:44","pubTimestamp":1781192652,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:44 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nAQN2M36LD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ADIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642233132","title":"Adial Pharmaceuticals acquires Azora Therapeutics, lines up up to $64 million private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2642233132","media":"Reuters","labels":["shareholding","corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642233132?lang=en_us&edition=fundamental","pubTime":"2026-06-11 23:44","pubTimestamp":1781192648,"startTime":"0","endTime":"0","summary":"Adial Pharmaceuticals acquired Azora Therapeutics, adding lead ulcerative colitis candidate AT177, an oral colon-targeted aryl hydrocarbon receptor agonist.A concurrent private placement targets up to USD 64 million gross proceeds, including USD 32 million upfront with a further USD 32 million tied to Phase 1 initiation.Upfront financing includes conversion of outstanding notes assumed in the acquisition, issued as pre-funded warrants priced at USD 2.75 each.Milestone tranches would issue additional pre-funded warrants with accompanying common warrants at a combined USD 2.75 per package.Proceeds are earmarked to advance AT177 through IND-enabling work, with Phase 1a and 1b studies in ulcerative colitis planned from mid-2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL11Sn67:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADIL","LU0314104364.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00B3QW5Z07.USD","BK4585","BK4007","LU2210150020.SGD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","BK4588","SG9999014013.SGD","SG9999014005.SGD","LU2095319765.USD","NDAQ","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","SG9999014021.USD","SG9999014039.USD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.adialpharma.com","stockEarnings":[{"period":"1week","weight":0.2014},{"period":"1month","weight":0.1886},{"period":"3month","weight":1.1548},{"period":"6month","weight":-0.3728},{"period":"1year","weight":-0.6936},{"period":"ytd","weight":-0.3927}],"compareEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":0.0017},{"period":"3month","weight":0.0366},{"period":"6month","weight":0.0796},{"period":"1year","weight":0.1819},{"period":"ytd","weight":0.0955}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.058856},{"month":2,"riseRate":0.25,"avgChangeRate":-0.031808},{"month":3,"riseRate":0,"avgChangeRate":-0.155549},{"month":4,"riseRate":0.375,"avgChangeRate":-0.03424},{"month":5,"riseRate":0.375,"avgChangeRate":-0.002623},{"month":6,"riseRate":0.375,"avgChangeRate":-0.130351},{"month":7,"riseRate":0.625,"avgChangeRate":0.108193},{"month":8,"riseRate":0.125,"avgChangeRate":-0.073571},{"month":9,"riseRate":0.375,"avgChangeRate":-0.037962},{"month":10,"riseRate":0.25,"avgChangeRate":-0.152838},{"month":11,"riseRate":0.375,"avgChangeRate":0.139286},{"month":12,"riseRate":0.375,"avgChangeRate":0.00671}],"exchange":"NASDAQ","name":"Adial Pharmaceuticals","nameEN":"Adial Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Adial Pharmaceuticals(ADIL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Adial Pharmaceuticals(ADIL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Adial Pharmaceuticals,ADIL,Adial Pharmaceuticals股票,Adial Pharmaceuticals股票老虎,Adial Pharmaceuticals股票老虎国际,Adial Pharmaceuticals行情,Adial Pharmaceuticals股票行情,Adial Pharmaceuticals股价,Adial Pharmaceuticals股市,Adial Pharmaceuticals股票价格,Adial Pharmaceuticals股票交易,Adial Pharmaceuticals股票购买,Adial Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Adial Pharmaceuticals(ADIL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Adial Pharmaceuticals(ADIL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}